Application of Magnetic Nanoparticles and Hyperthermia for the treatment of Pancreatic Cancer

Abstract

Pancreatic ductal adenocarcinoma is an orphan disease with a very poor prognosis, even when diagnosed early. The survival rate after 5 years is less than 5% and has not changed in the last 30 years despite tremendous efforts in the preclinical and clinical stages. In recent years, the use of nanotechnology-based approaches has been applied for the detection and treatment of multiple diseases. In this context, the NoCanTher consortium has been working to scale up under GMP (Good Manufacturing Practices) and ISO conditions and evaluate a nanoformulation based on magnetic nanoparticles for a combination therapy against this disease.

The main objective of the Nocanther project is the development of magnetic nanoparticles and bringing them to early clinical development for pancreatic cancer.

To achieve this objective, the following secondary objectives have been defined:

• Achieve nanotherapeutic scaling under certified conditions from synthesis in the laboratory to its implementation in clinical trials.
• Design and implement different preclinical studies in vitro and in vivo that allow obtaining preliminary data on the safety and efficacy of the developed nanoparticles.
• Develop the relevant documentation (including the investigational medical device dossier) for approval by the ethics committees and regulatory agencies (AEMPS) of a phase I security trial.